Skip to main content
Premium Trial:

Request an Annual Quote

Metrigenix, Neuralstem to Introduce DNA Chip for Neurodegenerative Disease in Q4

NEW YORK, Sept. 4 - Gene Logic spinoff Metrigenix and Neuralstem today said they will roll out a DNA chip for neurodegenerative-disease research within the next three months.

The chip, the first product from a collaboration between the two firms that dates back one year, will be based on Metrigenix's 4D array system and will contain genomic data modeled on Neuralstem's human CNS stem cells, the partners said.


Claiming that "the combination of microarray technology and human CNS gene information is ideal for screening compounds for ... toxicity," Metrigenix said Neuralstem's CNS cultures will be made available to 4D customers for discovery research and follow-up screening and validation.

Metrigenix said the deal with Neuralstem--its first since being spun off from Gene Logic--was designed to devise low-density oligo microarrays that can help researchers study gene expression in the central nervous system.


Terms of the deal called for Metrigenix to provide its flow-thru chip technology while College Park, Md.-based Neuralstem, a developer of stem-cell technology for the human central nervous system, contributes the content.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.